Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715883 | 0.99 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1MMP2NPSR1 | |
| SCHEMBL5566515 | 0.96 | ALDH1A1 (0.36) | ALDH1A1TSHRL3MBTL1NPSR1LMNA | |
| SCHEMBL4981840 | 0.89 | ALDH1A1 (0.34) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL13715850 | 0.89 | CYP2D6 (0.31) | NPSR1CYP2D6GPR55ADRA2AADRA2B | |
| SCHEMBL7475069 | 0.87 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL13715800 | 0.87 | HSD11B1 (0.31) | CYP2D6 | |
| SCHEMBL5565751 | 0.85 | BRD4 (0.30) | — | |
| SCHEMBL4978996 | 0.84 | ALDH1A1 (0.37) | ALDH1A1TSHRL3MBTL1NPSR1LMNA | |
| SCHEMBL13715775 | 0.83 | CYP2D6 (0.31) | NPSR1CYP2D6GPR55ADRA2AADRA2B | |
| SCHEMBL13715856 | 0.83 | POLB (0.37) | ALDH1A1TSHRL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572869-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572869-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2008-01-17 | — | — | US | disclosed |
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2008-01-17 | — | — | US | disclosed |
| US-7288613-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288613-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288613-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149011-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding N-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | ALDH1A1 369/4885TSHR 4785/4885L3MBTL1 3113/4885 |
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | ALDH1A1 361/4885TSHR 4783/4885L3MBTL1 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.